OTCMGLABF
Market cap40mUSD
Dec 27, Last price
0.55USD
Name
Gemina Laboratories Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-5m
L-12.75%
CFO
-3m
L-28.07%
Earnings
Jun 26, 2025
Profile
Gemina Laboratories Ltd., a biotechnology company, engages in the research, development, and commercialization of in-vitro diagnostics in Canada. The company develops novel surface functionalization chemistries for the detection of pathogens and biomarkers. It is developing POC Antigen COVID test, a point-of-care lateral flow assay test strip to test whether or not a person is currently infected with COVID-19. The company is headquartered in Vancouver, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2024‑01 | 2023‑01 | 2022‑01 | 2021‑01 | |
| Income | ||||
Revenues | ||||
Cost of revenue | 5,179 | 5,999 | 4,735 | |
Unusual Expense (Income) | ||||
NOPBT | (5,179) | (5,999) | (4,735) | |
NOPBT Margin | ||||
Operating Taxes | (118) | (185) | ||
Tax Rate | ||||
NOPAT | (5,179) | (5,881) | (4,551) | |
Net income | (5,217) -12.75% | (5,979) 26.28% | (4,735) 467.63% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 2,605 | 4,298 | 2,417 | |
BB yield | ||||
| Debt | ||||
Debt current | 279 | 43 | 41 | |
Long-term debt | 491 | 439 | 52 | |
Deferred revenue | ||||
Other long-term liabilities | ||||
Net debt | (225) | (596) | (1,064) | |
| Cash flow | ||||
Cash from operating activities | (3,244) | (4,510) | (3,872) | |
CAPEX | (41) | (80) | (10) | |
Cash from investing activities | (41) | (505) | 8 | |
Cash from financing activities | 3,203 | 3,941 | 4,138 | |
FCF | (4,296) | (4,629) | (4,545) | |
| Balance | ||||
Cash | 990 | 83 | 1,156 | |
Long term investments | 994 | 994 | ||
Excess cash | 995 | 1,078 | 1,156 | |
Stockholders' equity | (1,630) | (72) | 944 | |
Invested Capital | 530 | 241 | 46 | |
ROIC | ||||
ROCE | 470.90% | |||
| EV | ||||
Common stock shares outstanding | 72,453 | 60,190 | 47,659 | |
Price | ||||
Market cap | ||||
EV | ||||
EBITDA | (5,086) | (5,949) | (4,691) | |
EV/EBITDA | ||||
Interest | 19 | 539 | ||
Interest/NOPBT | ||||